STTK (Shattuck Labs) Retained Earnings : $-363.04 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Shattuck Labs's retained earnings for the quarter that ended in Sep. 2024 was $-363.04 Mil.

Shattuck Labs's quarterly retained earnings declined from Mar. 2024 ($-324.81 Mil) to Jun. 2024 ($-346.37 Mil) and declined from Jun. 2024 ($-346.37 Mil) to Sep. 2024 ($-363.04 Mil).

Shattuck Labs's annual retained earnings declined from Dec. 2021 ($-117.07 Mil) to Dec. 2022 ($-219.01 Mil) and declined from Dec. 2022 ($-219.01 Mil) to Dec. 2023 ($-306.31 Mil).

Shattuck Labs Retained Earnings Historical Data

The historical data trend for Shattuck Labs's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Retained Earnings Chart

Shattuck Labs Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-35.49

-72.09

-117.07

-219.01

-306.31

Shattuck Labs Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Retained Earnings	Get a 7-Day Free Trial															-288.62	-306.31	-324.81	-346.37	-363.04

Shattuck Labs Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Shattuck Labs (NAS:STTK) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Shattuck Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701

Website

https://www.shattucklabs.com

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Executives

Taylor Schreiber	director, officer: Chief Executive Officer	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Tyler Brous	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Stephen Stout	officer: See Remarks	C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Andrew R Neill	officer: See Remarks	1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla	officer: Chief Technical Officer	500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein	director	500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson	officer: General Counsel	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower	director, 10 percent owner, officer: Chairman	3317 BOWMAN AVE, AUSTIN TX 78703
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Arundathy N. Pandite	officer: Chief Medical Officer	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung	officer: Chief Business Officer	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744